Skip to main content
SpringerLink
Log in

Management of Metastatic Hormone-Sensitive Prostate Cancer (mHSPC): an Evolving Treatment Paradigm

  • Genitourinary Cancers (S Gupta, Section Editor)
  • Published:
Current Treatment Options in Oncology Aims and scope Submit manuscript

Opinion statement

Combination systemic therapy is now standard of care for all men with metastatic, hormone-sensitive prostate cancer (mHSPC). Patients with mHSPC should be treated with standard androgen deprivation therapy (ADT) and abiraterone acetate with prednisone or docetaxel (chemohormoanl therapy) unless there are contraindications to combination therapy. Based on the Chemohormonal Therapy Versus Androgen Ablation Randomized Trial for Extensive Disease in Prostate Cancer (CHAARTED) study subgroup analysis, chemohormonal therapy may be most beneficial in men with high-volume disease burden, as men with low-volume metastatic disease do not appear to experience a survival benefit with chemohormonal therapy, while abiraterone in combination with ADT appears to be beneficial across both disease volume subgroups. Decisions regarding whether to use chemohormonal therapy or abiraterone and ADT for men with mHSPC should integrate consideration of volume of disease burden, quality of life effects, duration of therapy, and patient preferences for treatment as there is no formally powered prospective head-to-head comparison of these options demonstrating superiority of one approach over the other. Treatment of the primary tumor with radiation should be considered in men with de novo low-volume metastatic disease as radiation is associated with prolonged survival and a tolerable toxicity profile. Men with de novo high-volume metastatic disease do not appear to have improved survival with radiation of the primary tumor. Numerous clinical trials are ongoing to evaluate treatment approaches that may benefit men with mHSPC. Radical prostatectomy in men with mHSPC in combination with optimal systemic therapy is currently being assessed in a clinical trial, but should not be considered outside of a clinical trial. Metastasis-directed therapy with radiotherapy directed at metastatic lesions is still investigational, but can be considered in clinical trials in men with oligometastatic disease. Multiple studies are enrolling worldwide for men with mHSPC, and these should be considered for all interested patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68(1):7–30.

    PubMed  Google Scholar 

  2. Dall’Era MA, deVere-White R, Rodriguez D, Cress R. Changing incidence of metastatic prostate cancer by race and age, 1988–2015. Eur Urol Focus. 2018; In press

  3. Weiner AB, Matulewicz RS, Eggener SE, Schaeffer EM. Increasing incidence of metastatic prostate cancer in the United States (2004–2013). Prostate Cancer Prostatic Dis. 2016;19(4):395–7.

    Article  CAS  PubMed  Google Scholar 

  4. Faiena I, Holden S, Cooperberg MR, et al. Prostate cancer screening and the goldilocks principle: how much is just right? J Clin Oncol. 2018;36(10):937–41.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Force USPST, Grossman DC, Curry SJ, et al. Screening for prostate cancer: US preventive services task force recommendation statement. JAMA. 2018;319(18):1901–13.

    Article  Google Scholar 

  6. Bill-Axelson A, Holmberg L, Garmo H, et al. Radical prostatectomy or watchful waiting in early prostate cancer. N Engl J Med. 2014;370(10):932–42.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Montgomery RB, Mostaghel EA, Vessella R, et al. Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res. 2008;68(11):4447–54.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Scher HI, Sawyers CL. Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis. J Clin Oncol. 2005;23(32):8253–61.

    Article  CAS  PubMed  Google Scholar 

  9. Stanbrough M, Bubley GJ, Ross K, et al. Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res. 2006;66(5):2815–25.

    Article  CAS  PubMed  Google Scholar 

  10. Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010;363(5):411–22.

    Article  CAS  PubMed  Google Scholar 

  11. Parker C, Nilsson S, Heinrich D, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med. 2013;369(3):213–23.

    Article  CAS  PubMed  Google Scholar 

  12. Petrylak DP, Tangen CM, Hussain MHA, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004;351(15):1513–20.

    Article  CAS  PubMed  Google Scholar 

  13. •• James ND, de Bono JS, Spears MR, et al. Abiraterone for prostate cancer not previously treated with hormone therapy. N Engl J Med. 2017;377(4):338–51 One of two large randomized controlled trials demonstrating the survival benefits of abiraterone in addition to androgen deprivations.

  14. •• James ND, Sydes MR, Clarke NW, et al. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet. 2016;387(10024):1163–77 One of two large randomized controlled trials demonstrating the survival benefits of docetaxel with androgen deprivations in men with metastatic hormone sensitive prostate cancer, specifically in men with high burden of metastatic disease.

  15. Sweeney CJ, Chen YH, Carducci M, et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med. 2015;373(8):737–46.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. • Boeve LMS, Hulshof M, Vis AN, et al. Effect on survival of androgen deprivation therapy alone compared to androgen deprivation therapy combined with concurrent radiation therapy to the prostate in patients with primary bone metastatic prostate cancer in a prospective randomised clinical trial: data from the HORRAD Trial. Eur Urol. 2019;75(3):410–18.

  17. Culp SH, Schellhammer PF, Williams MB. Might men diagnosed with metastatic prostate cancer benefit from definitive treatment of the primary tumor? V. Eur Urol. 2014;65(6):1058–66.

    Article  PubMed  Google Scholar 

  18. •Parker CC, James ND, Brawley CD, et al. Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial. Lancet. 2018;392(10162):2353–66.

  19. • Ost P, Reynders D, Decaestecker K, et al. Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence: a prospective, randomized, multicenter phase ii trial. J Clin Oncol. 2018;36(5):446 Randomized trial suggesting metastasis directed therapy could delay the need for androgen deprivation therapy in men with metastatic prostate cancer.

  20. Ploussard G, Gandaglia G, Borgmann H, et al. Salvage lymph node dissection for nodal recurrent prostate cancer: a systematic review. Eur Urol. 2018. In press.

  21. Zattoni F, Nehra A, Murphy CR, et al. Mid-term outcomes following salvage lymph node dissection for prostate cancer nodal recurrence status post-radical prostatectomy. Eur Urol Focus. 2016;2(5):522–31.

    Article  PubMed  Google Scholar 

  22. Collier A, Ghosh S, McGlynn B, Hollins G. Prostate cancer, androgen deprivation therapy, obesity, the metabolic syndrome, type 2 diabetes, and cardiovascular disease: a review. Am J Clin Oncol. 2012;35(5):504–9.

    Article  PubMed  Google Scholar 

  23. Smith MR, Lee WC, Brandman J, Wang Q, Botteman M, Pashos CL. Gonadotropin-releasing hormone agonists and fracture risk: a claims-based cohort study of men with nonmetastatic prostate cancer. J Clin Oncol. 2005;23(31):7897–903.

    Article  CAS  PubMed  Google Scholar 

  24. Tsai HK, D’Amico AV, Sadetsky N, Chen MH, Carroll PR. Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality. J Natl Cancer Inst. 2007;99(20):1516–24.

    Article  PubMed  Google Scholar 

  25. Hershman DL, Unger JM, Wright JD, et al. Adverse health events following intermittent and continuous androgen deprivation in patients with metastatic prostate cancer. JAMA Oncol. 2016;2(4):453–61.

    Article  PubMed  PubMed Central  Google Scholar 

  26. Mason MD, Clarke NW, James ND, et al. Adding celecoxib with or without zoledronic acid for hormone-naive prostate cancer: long-term survival results from an adaptive, multiarm, multistage, platform, randomized controlled trial. J Clin Oncol. 2017;35(14):1530.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Hellman S, Weichselbaum RR. Oligometastases. J Clin Oncol Off J Am Soc Clin Oncol. 1995;13(1):8–10.

    Article  CAS  Google Scholar 

  28. Soloway MS, Hardeman SW, Hickey D, et al. Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan. Cancer. 1988;61(1):195–202.

    Article  CAS  PubMed  Google Scholar 

  29. •• Kyriakopoulos CE, Chen YH, Carducci MA, et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer: long-term survival analysis of the randomized phase III E3805 CHAARTED Trial. J Clin Oncol. 2018;36(11):1080–7 Long-term follow-up of one of two large randomized controlled trials demonstrating the survival benefits of docetaxel with androgen deprivations in men with metastatic hormone sensitive prostate cancer, specically in men with high burden of metastatic disease.

  30. Graziani T, Ceci F, Castellucci P, et al. (11)C-Choline PET/CT for restaging prostate cancer. Results from 4,426 scans in a single-centre patient series. Eur J Nucl Med Mol Imaging. 2016;43(11):1971–9.

    Article  CAS  PubMed  Google Scholar 

  31. Nanni C, Schiavina R, Brunocilla E, et al. 18F-Fluciclovine PET/CT for the detection of prostate cancer relapse: a comparison to 11C-choline PET/CT. Clin Nucl Med. 2015;40(8):e386–91.

    Article  PubMed  Google Scholar 

  32. Lake ST, Greene KL, Westphalen AC, et al. Optimal MRI sequences for (68)Ga-PSMA-11 PET/MRI in evaluation of biochemically recurrent prostate cancer. EJNMMI Res. 2017;7(1):77.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  33. Chen Y, Sawyers CL, Scher HI. Targeting the androgen receptor pathway in prostate cancer. Curr Opin Pharmacol. 2008;8(4):440–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Shahinian VB, Kuo YF, Gilbert SM. Reimbursement policy and androgen-deprivation therapy for prostate cancer. N Engl J Med. 2010;363(19):1822–32.

    Article  CAS  PubMed  Google Scholar 

  35. Scher HI, Morris MJ, Stadler WM, et al. Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the prostate cancer clinical trials working group 3. J Clin Oncol. 2016;34(12):1402–18.

    Article  PubMed  PubMed Central  Google Scholar 

  36. Basaria S, Muller DC, Carducci MA, Egan J, Dobs AS. Hyperglycemia and insulin resistance in men with prostate carcinoma who receive androgen-deprivation therapy. Cancer. 2006;106(3):581–8.

    Article  CAS  PubMed  Google Scholar 

  37. Keating NL, O’Malley AJ, Freedland SJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer. J Natl Cancer Inst. 2010;102(1):39–46.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Keating NL, O’Malley AJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol. 2006;24(27):4448–56.

    Article  CAS  PubMed  Google Scholar 

  39. Smith MR, Finkelstein JS, McGovern FJ, et al. Changes in body composition during androgen deprivation therapy for prostate cancer. J Clin Endocrinol Metab. 2002;87(2):599–603.

    Article  CAS  PubMed  Google Scholar 

  40. Gao YF, He WY, He XY, Huang YL, Gou X. Exercise overcome adverse effects among prostate cancer patients receiving androgen deprivation therapy An update meta-analysis. Medicine. 2017;96(27): e7368

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  41. Daniell HW, Dunn SR, Ferguson DW, Lomas G, Niazi Z, Stratte PT. Progressive osteoporosis during androgen deprivation therapy for prostate cancer. J Urol. 2000;163(1):181–6.

    Article  CAS  PubMed  Google Scholar 

  42. Serpa Neto A, Tobias-Machado M, Esteves MA, et al. Bisphosphonate therapy in patients under androgen deprivation therapy for prostate cancer: a systematic review and meta-analysis. Prostate Cancer Prostatic Dis. 2012;15(1):36–44.

    Article  CAS  PubMed  Google Scholar 

  43. Alibhai SMH, Zukotynski K, Walker-Dilks C. Bone health and bone-targeted therapies for nonmetastatic prostate cancer RESPONSE. Ann Intern Med. 2018;168(6):459.

    Article  PubMed  Google Scholar 

  44. Smith MR, Halabi S, Ryan CJ, et al. Randomized controlled trial of early zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: results of CALGB 90202 ( Alliance). J Clin Oncol. 2014;32(11):1143.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  45. Gralow JR, Biermann JS, Farooki A, et al. NCCN Task force report: bone health in cancer care. J Natl Compr Cancer Netw. 2013;11(Suppl 3):S1–50 quiz S51.

    Article  Google Scholar 

  46. Raber J, Bongers G, LeFevour A, Buttini M, Mucke L. Androgens protect against apolipoprotein E4-induced cognitive deficits. J Neurosci. 2002;22(12):5204–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  47. Ramsden M, Nyborg AC, Murphy MP, et al. Androgens modulate beta-amyloid levels in male rat brain. J Neurochem. 2003;87(4):1052–5.

    Article  CAS  PubMed  Google Scholar 

  48. Gunlusoy B, Ceylan Y, Koskderelioglu A, et al. Cognitive effects of androgen deprivation therapy in men with advanced prostate cancer. Urology. 2017;103:167–72.

    Article  PubMed  Google Scholar 

  49. Alibhai SM, Timilshina N, Duff-Canning S, et al. Effects of long-term androgen deprivation therapy on cognitive function over 36 months in men with prostate cancer. Cancer. 2017;123(2):237–44.

    Article  PubMed  Google Scholar 

  50. Millikan RE, Wen S, Pagliaro LC, et al. Phase III trial of androgen ablation with or without three cycles of systemic chemotherapy for advanced prostate cancer. J Clin Oncol. 2008;26(36):5936–42.

    Article  PubMed  PubMed Central  Google Scholar 

  51. Gravis G, Fizazi K, Joly F, et al. Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial. Lancet Oncol. 2013;14(2):149–58.

    Article  CAS  PubMed  Google Scholar 

  52. Gravis G, Boher JM, Joly F, et al. Androgen deprivation therapy (ADT) plus docetaxel versus adt alone in metastatic non castrate prostate cancer: impact of metastatic burden and long-term survival analysis of the randomized phase 3 GETUG-AFU15 Trial. Eur Urol. 2016;70(2):256–62.

    Article  CAS  PubMed  Google Scholar 

  53. Sydes MR, Parmar MK, Mason MD, et al. Flexible trial design in practice - stopping arms for lack-of-benefit and adding research arms mid-trial in STAMPEDE: a multi-arm multi-stage randomized controlled trial. Trials. 2012;13:168.

    Article  PubMed  PubMed Central  Google Scholar 

  54. Sathianathen NJ, Philippou YA, Kuntz GM, et al. Taxane-based chemohormonal therapy for metastatic hormone-sensitive prostate cancer. Cochrane Database Syst Rev. 2018;10:CD012816.

  55. Morgans AK, Chen YH, Sweeney CJ, et al. Quality of life during treatment with chemohormonal therapy: analysis of E3805 chemohormonal androgen ablation randomized trial in prostate cancer. J Clin Oncol. 2018;36(11):1088–95.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  56. •• Fizazi K, Tran N, Fein L, et al. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N Engl J Med. 2017;377(4):352–60 One of two large randomized controlled trials demonstrating the survival benefits of abiraterone in addition to androgen deprivations.

    Article  CAS  PubMed  Google Scholar 

  57. Rydzewska LHM, Burdett S, Vale CL, et al. Adding abiraterone to androgen deprivation therapy in men with metastatic hormone-sensitive prostate cancer: a systematic review and meta-analysis. Eur J Cancer. 2017;84:88–101.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  58. Hoyle AP, Ali SA, James ND, et al. Effects of abiraterone acetate plus prednisone/prednisolone in high and low risk metastatic hormone sensitive prostate cancer. Annals of Oncology. 2018;29:722.

  59. Chi KN, Protheroe A, Rodriguez-Antolin A, et al. Patient-reported outcomes following abiraterone acetate plus prednisone added to androgen deprivation therapy in patients with newly diagnosed metastatic castration-naive prostate cancer (LATITUDE): an international, randomised phase 3 trial. Lancet Oncol. 2018;19(2):194–206.

    Article  CAS  PubMed  Google Scholar 

  60. Sydes MR, Spears MR, Mason MD, et al. Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol. Ann Oncol. 2018;29(5):1235–48.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  61. Armstrong AJ, Szmulewitz RZ, Petrylak DP, et al. Phase III study of androgen deprivation therapy (ADT) with enzalutamide (ENZA) or placebo (PBO) in metastatic hormone-sensitive prostate cancer (mHSPC): the ARCHES trial. J Clin Oncol. 2019;37(7_suppl):687.

    Article  Google Scholar 

  62. Janssen Announces ERLEADA® (apalutamide) Phase 3 TITAN study unblinded as dual primary endpoints achieved in clinical program evaluating treatment of patients with metastatic castration-sensitive prostate cancer. 2019. https://www.jnj.com/janssen-announces-erleada-apalutamide-phase-3-titan-study-unblinded-as-dual-primary-endpoints-achieved-in-clinical-program-evaluating-treatment-of-patients-with-metastatic-castration-sensitive-prostate-cancer. Accessed May 9, 2019.

  63. Attard G, Sydes MR, Mason MD, et al. Combining enzalutamide with abiraterone, prednisone, and androgen deprivation therapy in the STAMPEDE trial. Eur Urol. 2014;66(5):799–802.

    Article  CAS  PubMed  Google Scholar 

  64. Gillessen S, Gilson C, James N, et al. Repurposing metformin as therapy for prostate cancer within the STAMPEDE trial platform. Eur Urol. 2016;70(6):906–8.

    Article  PubMed  Google Scholar 

  65. Gilbert DC, Duong T, Sydes M, et al. Transdermal oestradiol as a method of androgen suppression for prostate cancer within the STAMPEDE trial platform. BJU Int. 2018;121(5):680–3.

    Article  PubMed  Google Scholar 

  66. Kaplan RN, Riba RD, Zacharoulis S, et al. VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature. 2005;438(7069):820–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  67. McAllister SS, Gifford AM, Greiner AL, et al. Systemic endocrine instigation of indolent tumor growth requires osteopontin. Cell. 2008;133(6):994–1005.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  68. Warde P, Mason M, Ding K, et al. Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial. Lancet. 2011;378(9809):2104–11.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  69. Widmark A, Klepp O, Solberg A, et al. Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial. Lancet. 2009;373(9660):301–8.

    Article  CAS  PubMed  Google Scholar 

  70. Satkunasivam R, Kim AE, Desai M, et al. Radical prostatectomy or external beam radiation therapy vs no local therapy for survival benefit in metastatic prostate cancer: a SEER-medicare analysis. J Urol. 2015;194(2):378–85.

    Article  PubMed  PubMed Central  Google Scholar 

  71. Rusthoven CG, Jones BL, Flaig TW, et al. Improved survival with prostate radiation in addition to androgen deprivation therapy for men with newly diagnosed metastatic prostate cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2016;34(24):2835–42.

    Article  CAS  Google Scholar 

  72. Loppenberg B, Dalela D, Karabon P, et al. The impact of local treatment on overall survival in patients with metastatic prostate cancer on diagnosis: a national cancer data base analysis. Eur Urol. 2017;72(1):14–9.

    Article  PubMed  Google Scholar 

  73. Parikh RR, Byun J, Goyal S, Kim IY. Local therapy improves overall survival in patients with newly diagnosed metastatic prostate cancer. Prostate. 2017;77(6):559–72.

    Article  PubMed  Google Scholar 

  74. Gratzke C, Engel J, Stief CG. Role of radical prostatectomy in metastatic prostate cancer: data from the Munich Cancer Registry. Eur Urol. 2014;66(3):602–3.

    Article  PubMed  Google Scholar 

  75. Heidenreich A, Fossati N, Pfister D, et al. Cytoreductive radical prostatectomy in men with prostate cancer and skeletal metastases. Eur Urol Oncol. 2018;1(1):46–53.

    Article  PubMed  Google Scholar 

  76. Potters L, Kavanagh B, Galvin JM, et al. American Society for Therapeutic Radiology and Oncology (ASTRO) and American College of Radiology (ACR) practice guideline for the performance of stereotactic body radiation therapy. Int J Radiat Oncol Biol Phys. 2010;76(2):326–32.

    Article  PubMed  Google Scholar 

  77. De Bleser E, Tran PT, Ost P. Radiotherapy as metastasis-directed therapy for oligometastatic prostate cancer. Curr Opin Urol. 2017;27(6):587–95.

    Article  PubMed  Google Scholar 

  78. Rischke HC, Schultze-Seemann W, Wieser G. et al. Strahlenther Onkol. 2015;191(4):310–20.

    Article  PubMed  Google Scholar 

  79. Jereczek-Fossa BA, Fanetti G, Fodor C, et al. Salvage stereotactic body radiotherapy for isolated lymph node recurrent prostate cancer: single institution series of 94 consecutive patients and 124 lymph nodes. Clin Genitourin Cancer. 2017;15(4):e623–32.

    Article  PubMed  Google Scholar 

  80. Ost P, Jereczek-Fossa BA, Van As N, et al. Pattern of progression after stereotactic body radiotherapy for oligometastatic prostate cancer nodal recurrences. Clin Oncol. 2016;28(9):e115–20.

    Article  CAS  Google Scholar 

  81. Schick U, Jorcano S, Nouet P, et al. Androgen deprivation and high-dose radiotherapy for oligometastatic prostate cancer patients with less than five regional and/or distant metastases. Acta Oncol. 2013;52(8):1622–8.

    Article  CAS  PubMed  Google Scholar 

  82. Decaestecker K, De Meerleer G, Lambert B, et al. Repeated stereotactic body radiotherapy for oligometastatic prostate cancer recurrence. Radiat Oncol. 2014;9:135.

    Article  PubMed  PubMed Central  Google Scholar 

  83. Siva S, Bressel M, Murphy DG, et al. Stereotactic abative body radiotherapy (SABR) for oligometastatic prostate cancer: a prospective clinical trial. Eur Urol. 2018;74(4):455–62.

    Article  PubMed  Google Scholar 

  84. Fossati N, Suardi N, Gandaglia G, et al. Identifying the optimal candidate for salvage lymph node dissection for nodal recurrence of prostate cancer: results from a large, multi-institutional analysis. Eur Urol. 2018;75(1):176–83.

Download references

Author information

Authors and Affiliations

  1. Department of Urology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA

    Adam B. Weiner MD & Oluwarotimi S. Nettey MD, MHS

  2. Department of Medicine, Northwestern University Feinberg School of Medicine, 676 N. St. Clair, Suite 850, Chicago, IL, 60611, USA

    Alicia K. Morgans MD, MPH

Authors
  1. Adam B. Weiner MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Oluwarotimi S. Nettey MD, MHS
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Alicia K. Morgans MD, MPH
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Alicia K. Morgans MD, MPH.

Ethics declarations

Conflict of Interest

Adam B. Weiner declares that he has no conflict of interest. Oluwarotimi S. Nettey declares that she has no conflict of interest. Alicia K. Morgans has received research funding (paid to her institution) from Bayer, and has received compensation for service on advisory boards from Astellas, Bayer, Sanofi, Genentech, AstraZeneca, and Janssen; has received compensation for service as a consultant from AstraZeneca; has received compensation for non-branded talks for education from Astellas; and has received compensation for research collaboration from Sanofi.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is part of the Topical Collection on Genitourinary Cancers

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Weiner, A.B., Nettey, O.S. & Morgans, A.K. Management of Metastatic Hormone-Sensitive Prostate Cancer (mHSPC): an Evolving Treatment Paradigm. Curr. Treat. Options in Oncol. 20, 69 (2019). https://doi.org/10.1007/s11864-019-0668-8

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11864-019-0668-8

Keywords

Search

Navigation